Characterisation of antibody-like molecules using human samples.
Research type
Research Study
Full title
Characterisation of antibody-like molecules that specifically bind to peptides commonly found in human samples.
IRAS ID
364197
Contact name
Lurdes Duarte
Contact email
Sponsor organisation
Isogenica
Clinicaltrials.gov Identifier
Online Booking (OB-29532), 25/PR/1445; Submission date: 09-10-2025, PR Committee
Duration of Study in the UK
5 years, 0 months, 0 days
Research summary
To date, several antibody-like proteins have been developed into drugs to be used in the treatment of immune-related disorders such as cancer, inflammation, and autoimmunity. Nevertheless, non-responding patients, development of resistance to treatment or unwanted excessive immune response has led to the need to develop alternative drugs. It is within the context of developing new drugs with improved characteristics and towards new targets that this research is being developed.
This research aims to discover antibody-like molecules that specifically recognise and bind to peptides on the target antigens, especially those found in human samples. The selected antibody-like molecules must perform a specific function like blocking a harmful interaction or activating an immune response. The final goal is to develop effective drugs for treating diseases with minimal side effects.
The characterisation of the antibody-like molecules will be developed by Isogenica in a laboratory research environment. The results obtained from this study will provide an essential dataset to inform on the suitability of the candidate antibody-like molecules to further development into the clinic.
REC name
London - Fulham Research Ethics Committee
REC reference
25/PR/1445
Date of REC Opinion
29 Oct 2025
REC opinion
Favourable Opinion